Last reviewed · How we verify
Azacytidine, HAG Regimen
Azacytidine is a DNA methyltransferase inhibitor that demethylates DNA and promotes differentiation of myelodysplastic cells.
Azacytidine is a DNA methyltransferase inhibitor that demethylates DNA and promotes differentiation of myelodysplastic cells. Used for Myelodysplastic syndromes, Acute myeloid leukemia (as part of HAG combination regimen).
At a glance
| Generic name | Azacytidine, HAG Regimen |
|---|---|
| Also known as | Azacytidine, HAG Regimen (HHT Cytarabine G-CSF) |
| Sponsor | Shenzhen Second People's Hospital |
| Drug class | DNA methyltransferase inhibitor |
| Target | DNA methyltransferase (DNMT) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Azacytidine inhibits DNA methylation by incorporating into DNA and trapping DNA methyltransferase, leading to hypomethylation of DNA. This reactivates silenced tumor suppressor genes and promotes cellular differentiation. The HAG regimen combines azacytidine with homoharringtonine and arsenic trioxide for enhanced anti-leukemic activity in hematologic malignancies.
Approved indications
- Myelodysplastic syndromes
- Acute myeloid leukemia (as part of HAG combination regimen)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Infection
- Injection site reactions
Key clinical trials
- New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PHASE2)
- Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML (PHASE2)
- Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy (PHASE4)
- PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azacytidine, HAG Regimen CI brief — competitive landscape report
- Azacytidine, HAG Regimen updates RSS · CI watch RSS
- Shenzhen Second People's Hospital portfolio CI